We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

200625:SZSEChongqing Changan Automobile Company Limited Analysis

Data as of 2026-06-14 - not real-time

HK$3.47

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at HK$3.47, sitting just above the computed support of HK$3.31 and below both the 50‑day (HK$3.69) and 200‑day (HK$4.16) simple moving averages, signaling a bearish bias. The 20‑day SMA at HK$3.43 is marginally under the price, but the price’s position under longer‑term averages reinforces downside pressure. RSI‑14 sits at 46, indicating neutral momentum, while the MACD line remains negative though the histogram turned modestly positive, hinting at a tentative bullish crossover that lacks strength. Volume has been on a decreasing trend, and the 30‑day volatility is elevated at roughly 28%, suggesting price swings may continue. A beta of 0.15 points to limited sensitivity to market moves, yet the high volatility and recent max drawdown of over 30% amplify the risk profile. Market sentiment is extremely bullish, with the Fear & Greed Index at 89.86 (“Extreme Greed”), which may be pricing in optimism beyond fundamentals.
Fundamentally, the company appears cheap – trailing P/E is about 9.6 and forward P/E drops to 3.8, while P/B is only 0.38 and price‑to‑sales is 0.21, placing it well below peers. However, earnings are thin (profit margin 1.9%) and operating cash flow is negative, resulting in a free‑cash‑flow deficit, and the payout ratio exceeds 100%, raising doubts about dividend sustainability despite the headline 10.85% yield. Revenue contracted 4.3% year‑over‑year and margins remain modest (gross 15.5%, operating 1.3%), reflecting a challenging operating environment. The balance sheet is cash‑rich (≈HK$39.9 bn) but levered, with a debt‑to‑equity of 1.59, and ROE is only 2.7%, indicating limited profitability. The upside‑downside projection shows roughly 9% upside against comparable downside, offering modest upside potential if the turnaround materializes. Given the blend of deep valuation discounts and significant cash‑flow strain, the stock may be positioned as a value play with high risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near support with bearish moving averages
  • Neutral RSI and weak MACD momentum
  • High dividend yield but unsustainable payout

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant valuation discounts (low P/E, P/B)
  • Negative operating and free cash flow
  • Potential upside of ~9% if turnaround occurs

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Deep value metrics relative to peers
  • Cash‑rich balance sheet providing cushion
  • Long‑term dividend yield attractive if cash flow improves

Key Metrics & Analysis

Financial Health

Revenue Growth-4.30%
Profit Margin1.89%
P/E Ratio9.6
ROE2.68%
ROA0.39%
Debt/Equity1.59
P/B Ratio0.4
Op. Cash FlowHK$-6310947840
Free Cash FlowHK$-15760020480

Technical Analysis

TrendBearish
RSI46.4
SupportHK$3.31
ResistanceHK$3.64
MA 20HK$3.43
MA 50HK$3.69
MA 200HK$4.16
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Target PriceHK$3.79
Upside/Downside9.17%
GradeUndervalued
TypeValue
Dividend Yield10.85%

Risk Assessment

Beta0.15
Volatility28.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.